TNFSF13B and lobular neoplasia: Belimumab is a human monoclonal antibody that inhibits BAFF and now is included in the recommended approach for patients with proliferative LN by KDIGO 2024 Clinical Practice Guideline for the Management of LN, both as induction therapy in combination with glucocorticoids and standard dose mycophenolic acid analogs or reduced-dose cyclophosphamide and as maintenance therapy in combination with low-dose glucocorticoids and mycophenolic acid analogs or azathioprine, based on efficacy demonstrated in BLISS-LN and the open label extension trials [15,35,121].